Intuitive Surgical Stock Has Been Plummeting. Is It Time to Buy?

Intuitive Surgical (ISRG) shares fell 6% after management at a healthcare conference highlighted international market budget constraints, pricing pressure in China, and potential for higher tariff impacts. However, the company's Q2 results showed robust growth, including 21% revenue and 17% procedure growth, with management guiding for continued expansion in 2025. While these headwinds contributed to a recent 20% stock pullback, the underlying business fundamentals remain strong, suggesting a potential long-term opportunity despite premium valuation risks if growth significantly slows or pricing pressure intensifies.

Analysis

Intuitive Surgical (ISRG) shares experienced a 6% decline and a cumulative 20% pullback over the last three months, primarily driven by management commentary on macroeconomic and operational headwinds. At a recent conference, the CFO highlighted several risks, including budget constraints in international markets, pricing pressure and domestic competition in China, and the potential for tariffs to create a gross margin headwind exceeding the previously guided 1-point in 2025. These concerns, however, contrast sharply with the company's robust Q2 performance, which featured 21% revenue growth to $2.44 billion, a 17% increase in global da Vinci procedures, and a 14% expansion of the installed base to 10,488 systems. Non-GAAP EPS also grew to $2.19 from $1.78 year-over-year. While management's 2025 procedure growth guidance of 15.5% to 17% implies moderation, it still signals strong expansion. The stock's valuation remains at a premium, trading near 50 times its annualized Q2 non-GAAP EPS, exposing it to compression risk should growth slow more than expected or if international pressures intensify.

Key Decisions for Investors

• Consider the current 20% stock price drawdown as a potential entry point for a long-term position, weighing the strong fundamental growth against the clearly articulated near-term headwinds.
• Monitor international procedure growth and system placement trends closely, as any significant deceleration below the guided 15.5%-17% range could trigger further valuation compression.
• Investors should note the company's plan to increase its reliance on leasing in international markets, as its success will be critical for navigating customer budget constraints and sustaining placement velocity.
• Given the premium valuation, any new positions should be scaled with an awareness of the heightened sensitivity to negative growth or margin surprises, particularly from tariffs or pricing pressure in China.